U.K. Cost Watchdog Rejects Lucentis’ Extended Use In Eye Disease
NICE’s draft rejection of Lucentis for use in secondary ophthalmologic indications comes as competition looms from Eylea in key AMD setting
NICE’s draft rejection of Lucentis for use in secondary ophthalmologic indications comes as competition looms from Eylea in key AMD setting